Dinalbuphine Sebacate
Phase 3Small molecule
Dinalbuphine Sebacate is one of 57 small molecule programs targeting Cesarean Section. It is currently in Phase 3.
2
Indications
8
Total Trials
3
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
83 competitors in Cesarean Section
#DrugCompanyPhaseTrials
1Fentanyl-Morphine
SSeoul National University Hospital
Phase 3
Dinalbuphine Sebacate
LLumosa Therapeutics Co., Ltd.
Phase 3
Ondansetron, Dexamethasone
KKing Khaled Eye Specialist Hospital
Phase 3
Acetaminophen/ibuprofen
SSeoul National University Hospital
Phase 3
Sebacoyl Dinalbuphine Ester
LLumosa Therapeutics Co., Ltd.
Phase 3
Morphine - .
RRambam Health Care Campus
Phase 3
Dynastat
PfizerPreclinical
Proamatine
TakedaPreclinical
Duragesic
CCephalon
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Postoperative Pain Management3 trials
AIN1 trial
Bariatric Surgery1 trial
Naldebain for Pain Control After Bariatric Surgery
Unknown status·—·Phase 2/3·NCT04651361·60 enrolled
Laparoscopic Cholecystectomy1 trial
Naldebain for Pain Management of Laparoscopic Cholecystectomy
Completed·—·Phase 2/3·NCT04808544·80 enrolled
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dinalbuphine Sebacate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLumosa Therapeutics Co., Ltd.